Bayer to acquire exclusive license from Cedilla Therapeutics on selective inhibitors in...

[cafead]

via

• Exclusive license agreement includes rights to develop and commercialize Cedilla’s CyclinE1/CDK2 inhibitors
• Assets are currently in pre-clinical development with potential to serve patients with high unmet need in underserved indications
• Collaboration further strengthens Bayer’s early pipeline in precision oncology

article source